Skip to main content

Nautilus Biotechnology, Inc.

For the period ended Dec 31, 2025. Filed Feb 26, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 26, 2026

NAUT$2.38+6.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Signatures

Pursuant to the requirements of Section 13 or 15(d) of the Exchange Act the Registrant has duly caused this Annual Report to be signed on its behalf by the undersigned, thereunto duly authorized.

NAUTILUS BIOTECHNOLOGY, INC.
By:/s/ Sujal Patel
Sujal Patel
Chief Executive Officer

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Sujal Patel and Anna Mowry, and each of them, as his or her true and lawful attorney-in-fact and agent with full power of substitution, for him or her in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact, proxy and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact, proxy and agent, or his or her substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed by the following persons in the capacities and on the dates indicated:

SignatureTitleDate
/s/ Sujal PatelChief Executive Officer, President and DirectorFebruary 26, 2026
Sujal Patel(Principal Executive Officer)
/s/ Anna MowryChief Financial OfficerFebruary 26, 2026
Anna Mowry(Principal Financial and Accounting Officer)
/s/ Melissa EpperlyDirectorFebruary 26, 2026
Melissa Epperly
/s/ Parag MallickDirectorFebruary 26, 2026
Parag Mallick
/s/ Matthew McIlwainDirectorFebruary 26, 2026
Matthew McIlwain
/s/ Farzad NazemDirectorFebruary 26, 2026
Farzad Nazem
/s/ Matthew L. PosardDirectorFebruary 26, 2026
Matthew L. Posard
/s/ Karen AkinsanyaDirectorFebruary 26, 2026
Karen Akinsanya
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.